+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Biotie Therapies Ltd
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MORE
UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylorthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA Key Recent Developments

Apr 16, 2020: RDMD secures $14 million in Series A Financing and announces partnership with UCB in Rare Neurodegenerative Disease
Feb 20, 2020: UCB shows strong performance in 2019 and increases the mid-term guidance for two core products
Dec 18, 2019: Expanding its portfolio of medicines: UCB to build new biotech manufacturing plant in Belgium
Oct 11, 2019: UCB acquires Ra Pharma for $2.1bn to enrich its rare disease portfolio
Oct 10, 2019: UCB to acquire Ra Pharmaceuticals in $2.1bn deal

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Biotie Therapies Ltd
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MORE
List of Tables

List of Figures

Section 1 - About the Company
  • UCB SA - Key Facts
  • UCB SA - Key Employees
  • UCB SA - Key Employee Biographies
  • UCB SA - Major Products and Services
  • UCB SA - History
  • UCB SA - Company Statement
  • UCB SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 – Company Analysis
  • Company Overview
  • UCB SA - Business Description
  • Product Category: Established Brands
  • Overview
  • Performance
  • Product Category: Immunology
  • Overview
  • Performance
  • Product Category: Neurology
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Target Markets
  • Performance
  • Geographical Segment: International Markets
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • UCB SA - Corporate Strategy
  • UCB SA - SWOT Analysis
  • SWOT Analysis - Overview
  • UCB SA - Strengths
  • UCB SA - Weaknesses
  • UCB SA - Opportunities
  • UCB SA - Threats
  • UCB SA - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • UCB SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Apr 16, 2020: RDMD secures $14 million in Series A Financing and announces partnership with UCB in Rare Neurodegenerative Disease
  • Feb 20, 2020: UCB shows strong performance in 2019 and increases the mid-term guidance for two core products
  • Dec 18, 2019: Expanding its portfolio of medicines: UCB to build new biotech manufacturing plant in Belgium
  • Oct 11, 2019: UCB acquires Ra Pharma for $2.1bn to enrich its rare disease portfolio
  • Oct 10, 2019: UCB to acquire Ra Pharmaceuticals in $2.1bn deal
  • Aug 21, 2019: Global Biopharma Company UCB supports Cognitant Group to Deliver Visual and Interactive Health Information for Patients
  • Jul 25, 2019: UCB’s strong performance enables continued investment into future growth drivers
  • Jul 02, 2019: DEARhealth announces collaboration with UCB to improve care delivery through new technology for patients living with epilepsy
  • Jun 04, 2019: UCB Boston research is advancing medical innovation
  • Mar 12, 2019: Ireland to lead €7 million Parkinson’s research project
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact
  • Disclaimer
List of Tables
  • UCB SA, Key Facts
  • UCB SA, Key Employees
  • UCB SA, Key Employee Biographies
  • UCB SA, Major Products and Services
  • UCB SA, History
  • UCB SA, Subsidiaries
  • UCB SA, Joint Venture
  • UCB SA, Key Competitors
  • UCB SA, Ratios based on current share price
  • UCB SA, Annual Ratios
  • UCB SA, Annual Ratios (Cont...1)
  • UCB SA, Annual Ratios (Cont...2)
  • UCB SA, Interim Ratios
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • UCB SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • UCB SA, Performance Chart (2015 - 2019)
  • UCB SA, Ratio Charts
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Servier Laboratories Ltd
  • Novartis AG
  • Merck Serono SA
  • Johnson & Johnson
  • GlaxoSmithKline Plc
  • Eli Lilly and Co
  • Biotie Therapies Ltd
  • Bausch Health Companies Inc
  • AstraZeneca Plc
  • Amgen Inc
Note: Product cover images may vary from those shown
Adroll
adroll